GoodRx Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GoodRx Holdings, Inc. on February 5, 2025, reporting events occurring on February 4, 2025. The filing discloses the appointment of a new Chief Financial Officer and Treasurer and details the associated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of Christopher A. McGinnis as Chief Financial Officer and Treasurer, effective February 4, 2025. He succeeds Romin Nabiey, who will continue serving as Chief Accounting Officer and principal accounting officer.
Management Commentary, Risks, and Unusual Items
Employment Agreement Terms:
- Base Salary: $500,000 annually.
- Signing Bonus: One-time cash payment of $250,000, subject to pro-rata repayment if employment terminates prior to the first anniversary (excluding death, disability, termination without cause, or good reason).
- Annual Bonus: Targeted at 100% of base salary, contingent on performance goals and continued employment.
- Equity Awards:
- Initial Restricted Stock Unit (RSU) Award with an aggregate value of $3,500,000.
- Initial Stock Option with an aggregate value of $3,500,000.
- Vesting Schedule: 25% vests on February 15, 2026, with the remainder vesting quarterly thereafter (1/16 per quarter), subject to continued employment.
- Severance: Mr. McGinnis is designated as a Tier 1 Participant in the Executive Severance Plan.
- Other Provisions: Includes a "best pay" provision regarding Section 280G excise taxes, non-disparagement, and standard confidentiality and non-competition covenants.
Investor Verification Checklist
- Verify the grant date and share count for the Initial RSU Award and Initial Option, as these depend on the closing share price or Black-Scholes valuation on the first trading day of the first open window following February 4, 2025.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and performance goals.
- Confirm the impact of the new CFO's background in pharmacy benefits management (Citizens Rx, Express Scripts) on the company's strategic direction.